A study with the NIHR Leeds CRF has recruited the first participant in the UK for an international study testing a new treatment for advanced lung cancer.
The SUNRAY-01 trial recruited its first UK patient this month at St James Hospital’s NIHR Leeds CRF and the Leeds Cancer Centre. SUNRAY-01 is a phase 3 global trial testing a treatment called olomorasib in metastatic non-small cell lung cancer (NSCLC).
Clinicians are studying if the addition of olomorasib alongside traditional treatment can improve outcomes for patients who have the KRAS G12C gene mutation, which is commonly associated with NSCLC.
Dr Katy Clarke, Consultant Thoracic Oncologist and Principal Investigator for SUNRAY-01, said: “It is a testament to the hard work of the whole team that we have the first UK participant in the SUNRAY-01 trial”.
“This trial is aimed at continuing the groundbreaking improvements in lung cancer survival we have seen over the last few years, and I believe this could be another practice changing trial.”
A big congratulations to the teams for this achievement!
For the latest information on clinical trial participation, please visit/contact the SUNRAY 1 – Health Research Authority website.